Table 1 Demographic and clinical characteristics of patients with major depressive disorder and healthy controls.

From: Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder

 

MDD (n = 114)

HC (n = 88)

p value

Age

43.51 ± 12.0

39.89 ± 14.05

0.055

Gender (female)

90

61

0.142

Education level

 Elementary and middle school

27

13

0.117

 High school or college/university

80

64

 Above graduate school

7

11

HDRS-17 score

14.81 ± 8.02

2.27 ± 2.10

<0.001

Duration of illness (months)

45.18 ± 47.47

  

FKBP5 gene rs1360780

 CC

72

58

0.725

 CT

39

29

 TT

3

1

 HWE

0.394

0.204

 CC

72

58

0.767

 CT + TT

42

30

Drug-naïve/Antidepressant

53/61

 

 CC

32/40

 

0.697

 CT + TT

21/21

 

Antidepressant type

 SSRI

30

  

 SNRI

10

  

 NDRI

6

  

 NaSSA

4

  

 Combination

11

  
  1. Data represent mean ± standard deviation for age, HDRS-17 scores, and duration of illness. The p values for distributions of gender, education level, FKBP5 genotype, and drug-naïve patients according to the genotype were obtained by chi-square test. The p values for comparisons of age and HDRS-17 scores were obtained by independent t-test. Allele frequencies (C/T): MDD patients 0.80/0.20, HC subjects 0.82/0.18. MDD, major depressive disorder; HC, healthy controls; HDRS-17, Hamilton Depression Rating Scale; HWE, Hardy-Weinberg equilibrium; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; NDRI, norepinephrine-dopamine reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; Combination, combinations of two or more types of antidepressant.
Back to article page